In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targacept, Inc.

http://www.targacept.com

Latest From Targacept, Inc.

Three OTC COVID-19 Tests Win FDA Clearance After Template Updates

Access Bio’s CareStart COVID-19 Antigen test gives results within 10 minutes, Becton, Dickinson’s BD Veritor within 15 minutes and InBios International’s SCoV-2 Ag Detect within 20 minutes. All three hold emergency use authorizations.

Diagnostics Coronavirus COVID-19

Korea Q3 Roundup: China Sales, Prescription Drugs, Vaccines Boost Results

Notable third-quarter developments at major Korean pharma firms included the domestic reimbursement of Yuhan’s Leclaza, the approval of Hanmi’s Rolontis and SK Bioscience's approval filing for Novavax's COVID-19 vaccine for supply in the country, a roundup of results by Scrip shows.

South Korea Companies

Cautious Optimism For Alzheimer's Mounts Among Industry R&D Leaders

Some big pharma R&D leaders have signaled enhanced interest in neuroscience R&D – and Alzheimer's more specifically – following FDA's approval of Biogen's Aduhelm based on biomarkers.

Neurology Research & Development

AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid

Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.

Sales & Earnings Business Strategies
See All

Company Information

UsernamePublicRestriction

Register